We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor. We also found markers for sensitivity to taxane-based therapies, especially albumin-bound paclitaxel. Exploring the biology of rare malignancies by CLIA certified labs may be reasonable strategy for the development of targeted treatments.
No takes yet. Share an insight, caveat, or question.
Jardim et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: